Asahi Kasei Pharma Eyes Global Expansion Of Diagnostics Business
This article was originally published in PharmAsia News
Japan's Asahi Kasei Pharma plans an expansion of its diagnostics business by developing new products and selling its blood-sugar reagents in India and the U.S.
You may also be interested in...
A draft guidance document by the US FDA that tackles medical device cybersecurity will likely be issued in the next several months, says Linda Ricci, a health scientist for the agency’s Office of Device Evaluation. Check out her comments on cybersecurity here.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.